Skip to main content
SpringerLink
Log in
Book cover

Cytokines and Chemokines in Infectious Diseases Handbook pp 345–359Cite as

Interleukin-2 for the Treatment of HIV Infection

  • Chapter

  • 171 Accesses

Part of the book series: Infectious Disease ((ID))

Abstract

Interleukin (IL)-2 was originally purified as a “T-cell growth factor” (TCGF) inducing the survival of human T-lymphocytes in vitro (1). Shortly after this, a 19-kDa molecule was definitively named IL-2 (2,3) and was shown early to interact with a cell surface receptor identified by the anti-Tac monoclonal antibody (mAb) (4,5). This mAb was later shown to recognize the α-chain (CD25) low-affinity receptor complex conferring high-affinity binding (10-11 M) to the (β/γ-chain IL-2 receptor shared with other cytokines (6,7). In 1983, the first DNA clone of IL-2 was obtained (8).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Morgan, D.A., Ruscetti, F.W., and Gallo, R. (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007–1008.

    Article  PubMed  CAS  Google Scholar 

  2. Smith, K.A. (1980) T-cell growth factor. Immunol. Rev. 51, 337–357.

    Article  PubMed  CAS  Google Scholar 

  3. Watson, J. and Mochizuki, D. (1980) Interleukin 2: a class of T cell growth factors. Immunol. Rev. 51, 257–278.

    Article  PubMed  CAS  Google Scholar 

  4. Robb, R.J., Munck, A., and Smith, K.A. (1981) T Cell growth factor receptors. Quantitation, specificity, and biological relevance. J. Exp. Med. 154, 1455–1474.

    Article  PubMed  CAS  Google Scholar 

  5. Depper, J.M., Leonard, W.J., Robb, R.J., Waldmann, T.A., and Greene W.C. (1983) Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J. Immunol. 131, 690–696.

    PubMed  CAS  Google Scholar 

  6. Leonard, W.J. and O’Shea, J.J. (1998) Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293–322.

    Article  PubMed  CAS  Google Scholar 

  7. Waldmann, T.A. and Tagaya, Y. (1999) The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17, 19–49.

    Article  PubMed  CAS  Google Scholar 

  8. Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C, Kashima, N., Yoshimoto, R., et al. (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305–310.

    Article  PubMed  CAS  Google Scholar 

  9. Schwartz, D.H., Skowron, G., and Merigan, T.C. (1991) Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J. Acquired Immune Defic. Syndrome 4, 11–23.

    CAS  Google Scholar 

  10. Kovacs, J.A., Baseler, M., Dewar, R.J., Vogel, S., Davey, R.T., Jr., Falloon, J., et al. (1995) Increases in CD4 T lymphocytes with intermittent courses of interleukin- 2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332, 567–575.

    Article  PubMed  CAS  Google Scholar 

  11. Kovacs, J.A., Vogel, S., Albert, J.M., Falloon, J., Davey, R.T., Jr., Walker, R.E., et al. (1996) Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350–1356.

    Article  PubMed  CAS  Google Scholar 

  12. Wood, R., Montoya, J.G., Kundu, S.K., Schwartz, D.H., and Merigan, T.C. (1993) Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J. Infect. Dis. 167,519–525.

    Article  PubMed  CAS  Google Scholar 

  13. Jacobson, E.L., Pilaro, F., and Smith, K.A. (1996) Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 93, 10,405–10,410.

    Article  CAS  Google Scholar 

  14. Teppler, H., Kaplan, G., Smith, K.A., Montana, A.L., Meyn, P., and Cohn, Z.A. (1993) Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. 111, 483–492.

    Article  Google Scholar 

  15. McMahon, D.K., Armstrong, J.A., Huang, X.L., Rinaldo, C.R., Jr., Gupta, P., Whiteside, T.L., et al. (1994) A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 8, 59–66.

    Article  PubMed  CAS  Google Scholar 

  16. Mazza, P., Bocchia, M., Tumietto, F., Costigliola, P., Coronado, O., Bandini, G., et al. (1992) Recombinant interleukin-2 (rIL-2) in acquired immune deficiency syndrome (AIDS): preliminary report in patients with lymphoma associated with HIV infection. Eur. J. Haematol. 49, 1–6.

    Article  PubMed  CAS  Google Scholar 

  17. Schnittman, S.M., Vogel, S., Baseler, M., Lane, H.C., and Davey, R.T., Jr. (1994) A phase I study of interferon-alpha 2b in combination with interleukin- 2 in patients with human immunodeficiency virus infection. J. Infect. Dis. 169, 981–989.

    Article  PubMed  CAS  Google Scholar 

  18. Klimas, N., Patarca, R., Walling, J., Garcia, R., Mayer, V., Moody, D., et al. (1994) Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 8, 1073–1081.

    Article  PubMed  CAS  Google Scholar 

  19. Bernstein, Z.P., Porter, M.M., Gould, M., Lipman, B., Bluman, E.M., Stewart, C.C., et al. (1995) Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86, 3287–3294.

    PubMed  CAS  Google Scholar 

  20. De Paoli, P., Zanussi, S., Simonelli, C, Bortolin, M.T., D’Andrea, M., Crepaldi, C, et al. (1997) Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J. Clin. Invest. 100, 2737–2743.

    Article  PubMed  Google Scholar 

  21. Levy, Y., Capitant, C, Houhou, S., Carriere, I., Viard, J.P., Goujard, C, et al. (1999) Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 353, 1923–1929.

    Article  PubMed  CAS  Google Scholar 

  22. Zanussi, S., Simonelli C, Bortolin M.T., D’Andrea M., Crepaldi C, Vaccher E., et al. (1999) Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin. Exp. Immunol. 116, 486–492.

    Article  PubMed  CAS  Google Scholar 

  23. Losso, M.H., Belloso, W.H., Emery, S., Benetucci, J.A., Cahn, P.E., Lasala, M.C., et al. (2000) A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J. Infect. Dis. 181, 1614–1621.

    Article  PubMed  CAS  Google Scholar 

  24. Arno, A., Ruiz, L., Juan, M., Jou, A., Balague, M., Zayat, M.K., et al. (1999) Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <250/(iL CD4 T cells and undetectable plasma viral load. J. Infect. Dis. 180, 56–60.

    Article  PubMed  CAS  Google Scholar 

  25. David, D., Nait-Ighil, L., Dupont, B., Maral, J., Gachot, B., and Theze, J. (2001) Rapid effect of interleukin-2 therapy in human immunodeficiency virus- infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J. Infect. Dis. 183, 730–735.

    Article  PubMed  CAS  Google Scholar 

  26. Zanussi, S., Simonelli, C, Bortolin, M.T., D’Andrea, M., Comar, M., Tirelli, U., et al. (1999) Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients. AIDS Res. Hum. Retroviruses 15, 97–103.

    Article  PubMed  CAS  Google Scholar 

  27. Simonelli, C, Zanussi, S., Sandri, S., Comar, M., Lucenti, A., Talamini, R., et al. (1999) Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J. Acquired Immune Defic. Syndrome Hum. Retrovir. 20, 20–27.

    Article  CAS  Google Scholar 

  28. Hengge, U.R., Goos, M., Esser, S., Exner, V., Dotterer, H., Wiehler, H., et al. (1998) Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 12, F225-F234.

    Article  PubMed  CAS  Google Scholar 

  29. De Paoli, P., Zanussi, S., Caggiari, L., Bortolin M.T., D’Andrea M., Simonelli C. et al. (1999) Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. J. Clin. Immunol. 19, 317–325.

    Article  PubMed  Google Scholar 

  30. Davey, R.T., Jr., Chaitt, D.G., Albert, J.M., Piscitelli, S.C., Kovacs, J.A., Walker, R.E., et al. (1999) A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 179, 849–858.

    Article  PubMed  CAS  Google Scholar 

  31. Carr, A., Emery S., Lloyd A., Hoy J., Garsia R., French M., et al. (1998) Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. J. Infect. Dis. 178, 992–999.

    Article  PubMed  CAS  Google Scholar 

  32. Weissman, D., Dybul, M., Daucher, M.B., Davey, R.T., Jr., Walker, R.E., and Kovacs J.A. (2000) Interleukin-2 up-regulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. J. Infect. Dis. 181, 933–938.

    Article  PubMed  CAS  Google Scholar 

  33. Blanco, J., Cabrera, C., Jou, A., Ruiz, L., Clotet, B. and Este, J.A. (1999) Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 13, 547–555.

    Article  PubMed  CAS  Google Scholar 

  34. Zou, W., Foussat, A., Houhou, S., Durand-Gasselin, I., Dulioust, A., Bouchet, L., et al. (1999) Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV- infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. AIDS 13, 455–463.

    Article  PubMed  CAS  Google Scholar 

  35. Horak, I., Lohler, J., Ma, A., and Smith, K.A. (1995) Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol. Rev. 148, 35–44.

    Article  PubMed  CAS  Google Scholar 

  36. Hunig, T. and Schimpl, A. (1998) The IL-2 deficiency syndrome. A lethal disease caused by abnormal lymphocyte survival, in Cytokine Knockouts (Durum, S.K. and Muegge, K., eds.), Humana, Totowa, NJ, pp. 1–19.

    Google Scholar 

  37. Refaeli, Y., Van Parijs, L., London, C.A., Tschopp, J., and Abbas, A.K. (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8, 615–623.

    Article  PubMed  CAS  Google Scholar 

  38. Espinoza-Delgado, I., Bosco, M.C., Musso, T., Gusella, G.L., Longo, D.L., and Varesio, L. (1995) Interleukin-2 and human monocyte activation. J. Leukocyte Biol. 57, 13–19.

    PubMed  CAS  Google Scholar 

  39. Ben Aribia, M.H., Leroy, E., Lantz, O., Metivier, D., Autran, B., Charpentier, B., et al. (1987) rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2. J. Immunol. 139, 443–451.

    PubMed  CAS  Google Scholar 

  40. Oliva, A., Kinter, A.L., Vaccarezza, M., Rubbert, A., Catanzaro, A., Moir, S., et al. (1998) Natural killer cells from human immunodeficiency virus (HlV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102, 223–231.

    Article  PubMed  CAS  Google Scholar 

  41. Mule, J.J., Shu, S., Schwarz, S.L., and Rosenberg, S.A. (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487–1489.

    Article  PubMed  CAS  Google Scholar 

  42. Yu, T.K., Caudell, E.G., Smid, C., and Grimm, E. A. (2000) IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 164, 6244–6251.

    PubMed  CAS  Google Scholar 

  43. Liu, C.C., Perussia, B., and Young, J.D. (2000) The emerging role of IL-15 in NK-cell development. Immunol. Today 21, 113–116.

    Article  PubMed  CAS  Google Scholar 

  44. Lanier, L.L. and Bakker, A.B. (2000) The ITAM-bearing transmembrane adaptor DAP 12 in lymphoid and myeloid cell function. Immunol. Today 21, 611–614.

    Article  PubMed  CAS  Google Scholar 

  45. Mingari, M.C., Ponte, M., Vitale, C., Bellomo, R. and Moretta, L. (2000) Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum. Immunol. 61, 44–50.

    Article  PubMed  CAS  Google Scholar 

  46. Rosenberg, S.A. (1984) Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J. Biol. Response Modifiers 3, 501–511.

    CAS  Google Scholar 

  47. Rosenberg, S.A. (2000) Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 6(Suppl 1), S2–7.

    PubMed  Google Scholar 

  48. Barre-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871.

    Article  PubMed  CAS  Google Scholar 

  49. Gallo, R.C., Sarin, P.S., Gelmann, E.P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V.S., et al. (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865–867.

    Article  PubMed  CAS  Google Scholar 

  50. Hazan, U., Thomas, D., Alcami, J., Bachelerie, F., Israel, N., Yssel, H., et al. (1990) Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription. Proc. Natl. Acad. Sci. USA 87, 7861–7865.

    Article  PubMed  CAS  Google Scholar 

  51. Zhang, Z., Schuler, T., Zupancic, M., Wietgrefe, S., Staskus, K.A., Reimann, K.A., et al. (1999) Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286, 1353–1357.

    Article  PubMed  CAS  Google Scholar 

  52. Vyakarnam, A., McKeating, J., Meager, A., and Beverley, P.C. (1990) Tumour necrosis factors (oc,p) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS, 4, 21–27.

    Article  PubMed  CAS  Google Scholar 

  53. Ramilo, O., Bell, K.D., Uhr, J.W., and Vitetta, E.S. (1993) Role of CD25+ and CD25-T cells in acute HIV infection in vitro. J. Immunol. 150, 5202–5208.

    PubMed  CAS  Google Scholar 

  54. Kinter, A.L., Poli, G., Fox, L., Hardy, E., and Fauci, A.S. (1995) HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J. Immunol. 154, 2448–2459.

    PubMed  CAS  Google Scholar 

  55. Kinter, A.L., Bende, S.M., Hardy, E.C., Jackson, R., and Fauci, A.S. (1995) Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc. Natl. Acad. Sci. USA 92, 10,985–10,989.

    Article  CAS  Google Scholar 

  56. Lusso, P. (2000) Chemokines and viruses: the dearest enemies. Virology 273, 228–240.

    Article  PubMed  CAS  Google Scholar 

  57. Walker, C.M., Moody, D.J., Stites, D.P., and Levy, J.A. (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234, 1563–1566.

    Article  PubMed  CAS  Google Scholar 

  58. Poli, G. (1999) Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. Eur. J. Clin. Invest. 29, 723–732.

    Article  PubMed  CAS  Google Scholar 

  59. Simmons, G., Reeves, J.D., Hibbitts, S., Stine, J.T., Gray, P.W., Proudfoot, A.E., and Clapham, P.R. (2000) Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 177, 112–126.

    Article  PubMed  CAS  Google Scholar 

  60. Loetscher, P., Seitz M., Baggiolini, M., and Moser, B. (1996) Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184, 569–577.

    Article  PubMed  CAS  Google Scholar 

  61. Plana, M., Garcia, F., Gallart, T., Tortajada, C., Soriano, A., Palou, E., et al. (2000) Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 14, 1921–1933.

    Article  PubMed  CAS  Google Scholar 

  62. Kutza, J., Hayes, M.P., and Clouse, K.A. (1998) Interleukin-2 inhibits HIV-1 replication in human macrophages by modulating expression of CD4 and CC-chemokine receptor-5. AIDS 12, F59-F64.

    Article  PubMed  CAS  Google Scholar 

  63. Bleul, C.C., Wu, L., Hoxie, J.A., Springer, T.A., and Mackay, C.R. (1997) The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94, 1925–1930.

    Article  PubMed  CAS  Google Scholar 

  64. Unutmaz, D., Xiang, W., Sunshine, M.J., Campbell, J., Butcher, E., and Littman D.R. (2000) The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J. Immunol. 165, 3284–3292.

    PubMed  CAS  Google Scholar 

  65. Inngjerdingen, M., Damaj, B., and Maghazachi, A.A. (2001) Expression and regulation of chemokine receptors in human natural killer cells. Blood 97, 367–375.

    Article  PubMed  CAS  Google Scholar 

  66. Kern, P., Toy, J., and Dietrich, M. (1985) Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut 50, 1–6.

    Article  PubMed  CAS  Google Scholar 

  67. Ernst, M., Kern, P., Flad, H.D., and Ulmer, A.J. (1986) Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS- related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). J. Clin. Immunol. 6, 170–181.

    Article  PubMed  CAS  Google Scholar 

  68. Volberding, P., Moody, D.J., Beardslee, D., Bradley, E.C., and Wofsy, C.B. (1987) Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res. Hum. Retroviruses 3, 115–124.

    Article  PubMed  CAS  Google Scholar 

  69. Schwartz, D.H. and Merigan, T.C. (1990) Interleukin-2 in the treatment of HIV disease. Biotherapy 2, 119–136.

    Article  PubMed  CAS  Google Scholar 

  70. Tambussi, G., Ghezzi, S., Nozza, S., Vallanti, G., Magenta, L., Guffanti, M., et al. (2001) Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J. Infect. Dis. 183, 1476–1484.

    Article  PubMed  CAS  Google Scholar 

  71. Davey, R.T., Jr., Chaitt, D.G., Piscitelli, S.C., Wells, M., Kovacs, J.A., Walker, R.E., et al. (1997) Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 175, 781–789.

    Article  PubMed  CAS  Google Scholar 

  72. Miller, K.D., Spooner, K., Herpin, B.R., Rock-Kress, D., Metcalf, J.A., Davey, R.T., Jr., et al. (2001) Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion. Clin. Immunol. 99, 30–42.

    Article  PubMed  CAS  Google Scholar 

  73. Emery, S., Capra W.B., Cooper D.A., Mitsuyasu R.T., Kovacs J.A., Vig P., et al. (2000) Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J. Infect. Dis. 182, 428–34.

    Article  PubMed  CAS  Google Scholar 

  74. Davey, R.T., Jr., Murphy R.L., Graziano F.M., Boswell S.L., Pavia A.T., Cancio M., et al. (2000) Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA 284, 183–189.

    Article  PubMed  CAS  Google Scholar 

  75. Lentsch, A.B., Miller, F.N., and Edwards, M.J. (1999) Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol. Immunother. 47, 243–248.

    Article  PubMed  CAS  Google Scholar 

  76. Lane, H.C., Siegel, J.P., Rook, A.H., Masur, H., Gelmann, E.P., Quinnan, G.V., and Fauci, A.S. (1984) Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J. Biol. Response Modifiers 3, 512–516.

    CAS  Google Scholar 

  77. Piscitelli, S.C., Forrest A., Vogel S., Chaitt D., Metcalf J., Stevens R., et al. (1998) Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 64, 492–98.

    Article  PubMed  CAS  Google Scholar 

  78. Khatri, V.P., Fehniger T.A., Baiocchi R.A., Yu F., Shah M.H., Schiller D.S., et al. (1998) Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 101, 1373–1378.

    Article  PubMed  CAS  Google Scholar 

  79. Piscitelli, S.C., Wells, M.J., Metcalf, J.A., Baseler, M., Stevens, R. and Davey, R.T., Jr. (1996) Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy 16, 754–759.

    PubMed  CAS  Google Scholar 

  80. Piscitelli, S.C., Vogel, S., Figg, W.D., Raje, S., Forrest, A., Metcalf, J.A., et al. (1998) Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 18, 1212–1216.

    PubMed  CAS  Google Scholar 

  81. Lafeuillade, A., Poggi, C, Chadapaud, S., Hittinger, G., Chouraqui, M., Pisapia, M., et al. (2001) Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acquired Immune Defic. Syndrome 26, 44–55.

    CAS  Google Scholar 

  82. Katlama, C, Duvivier, C, Chouquet, C, Autran, B., Carcelain, G., De Sa, M., et al. (2000) ILSTIM (ANRS 082)—a randomized comparative open-label study of interleukin-2 (IL2) in patients with CD4 <200 despite effective HAART. 7th Conference on Retroviruses and Opportunistic Infections, p. 177 (abstract).

    Google Scholar 

  83. De Boer, R.J. and Perelson, A.S. (1998) Target cell limited and immune control models of HIV infection: a comparison. J. Theor.Biol. 190,201–214.

    Article  PubMed  Google Scholar 

  84. de Jong, M.D., de Boer, R.J., de Wolf, F., Foudraine, N.A., Boucher, C.A., Goudsmit, J., et al. (1997) Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 11, F79-F84.

    Article  PubMed  Google Scholar 

  85. Davey, R.T., Jr., Bhat N., Yoder C, Chun T.W., Metcalf J.A., Dewar R., et al. (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15,109–15,114.

    Article  CAS  Google Scholar 

  86. Bovolenta, C, Camorali, L., Lorini, A.L., Vallanti, G., Ghezzi, S., Tambussi, G., et al. (1999) In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/Late simian virus 40 factor. J. Immunol. 163, 6892–6897.

    PubMed  CAS  Google Scholar 

  87. Margolis, D.M., Somasundaran, M., and Green, M.R. (1994) Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J. Virol. 68, 905–910.

    PubMed  CAS  Google Scholar 

  88. Bovolenta, C, Camorali, L., Lorini, A.L., Ghezzi, S., Vicenzi, E., Lazzarin, A. and Poli, G. (1999) Constitutive activation of STATs upon In vivo human immunodeficiency virus infection. Blood 94, 4202–4209.

    PubMed  CAS  Google Scholar 

  89. Pandolfi, F., Pierdominici, M, Marziali, M., Bernardi, M., Antonelli, G., Galati, V., et al. (2000) Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HA ART. Clin. Immunol. 94, 153–159.

    Article  PubMed  CAS  Google Scholar 

  90. Chun, T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., et al. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5,651–655.

    Article  PubMed  CAS  Google Scholar 

  91. Chun, T.W., Davey, R.T., Jr., Ostrowski, M., Shawn Justement, J., Engel, D., Mullins, J.I., et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti- retroviral therapy. Nat. Med. 6, 757–761.

    Article  PubMed  CAS  Google Scholar 

  92. Kovacs, J.A., Imamichi H., Vogel S., Metcalf J.A., Dewar R.L., Baseler M., et al. (2000) Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. J. Infect. Dis. 182, 1063–1069.

    Article  PubMed  CAS  Google Scholar 

  93. Dianzani, F., Antonelli, G., Aiuti, F., Turriziani, O., Riva, E., Capobianchi, M.R., et al. (2000) The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2. IRHAN Study Group. Antiviral Res. 45, 95–99.

    Article  PubMed  CAS  Google Scholar 

  94. Clark, A.G., Holodniy, M., Schwartz, D.H., Katzenstein, D.A., and Merigan, T.C. (1992) Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J. Acquired Immune Defic. Syndrome 5, 52–59.

    CAS  Google Scholar 

  95. Pantaleo, G., Koenig, S., Baseler, M., Lane, H.C., and Fauci, A.S. (1990) Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J. Immunol. 144, 1696–1704.

    PubMed  CAS  Google Scholar 

  96. Liu, Z., Cumberland, W.G., Hultin, L.E., Prince, H.E., Detels, R., and Giorgi, J.V. (1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquired Immune Defic. Syndrome Hum. Retrovir. 16, 83–92.

    Article  CAS  Google Scholar 

  97. Shearer, G.M. (1998) HIV-induced immunopathogenesis. Immunity 9, 587–593.

    Article  PubMed  CAS  Google Scholar 

  98. Shevach, E.M. (2000) Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423–449.

    Article  PubMed  CAS  Google Scholar 

  99. Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., et al. (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440.

    Article  PubMed  CAS  Google Scholar 

  100. Read, S., Malmstrom, V., and Powrie F. (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295–302.

    Article  PubMed  CAS  Google Scholar 

  101. Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., et al. (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310.

    Article  PubMed  CAS  Google Scholar 

  102. David, D., Bani, L., Moreau, J.L., Treilhou, M.P., Nakarai, T., Joussemet, M., et al. (1998) Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc. Natl. Acad. Sci. USA 95, 11,348–11,353.

    Article  CAS  Google Scholar 

  103. Moreau, J.L., Chastagner, P., Tanaka, T., Miyasaka, M., Kondo, M., Sugamura, K., et al. (1995) Control of the IL-2 responsiveness of B lymphocytes by IL-2 and IL-4. J. Immunol. 155, 3401–3408.

    PubMed  CAS  Google Scholar 

  104. Teppler, H., Kaplan, G., Smith, K., Cameron, P., Montana, A., Meyn, P., et al. (1993) Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J. Infect. Dis. 167, 291–298.

    Article  PubMed  CAS  Google Scholar 

  105. Vaith, P., Maas D., Feigl, D., Hauke, G., Lang, B., Oepke, G., et al. (1985) In vitro and in vivo studies with interleukin 2 (IL-2) and various immunostimulants in a patient with AIDS. Immun. Infekt. 13, 51–63.

    PubMed  CAS  Google Scholar 

  106. Kelleher, A.D., Roggensack, M., Emery, S., Carr, A., French, M.A., and Cooper, D.A. (1998) Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin. Exp. Immunol. 113, 85–91.

    Article  PubMed  CAS  Google Scholar 

  107. Aladdin, H., Larsen, C.S., Moller, B.K., Ullum, H., Buhl, M.R., Gerstoft, J., et al. (2000) Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients. Scand. J. Immunol. 51, 168–175.

    Article  PubMed  CAS  Google Scholar 

  108. Zou, W., Foussat, A., Capitant, C, Durand-Gasselin, I., Bouchet, L., Galanaud, P., et al. (1999) Acute activation of CD8+ T lymphocytes in interleukin-2-treated HIV-infected patients. ANRS-048 IL-2 Study Group. Agence Nationale de Recherches sur le SIDA. J. Acquired Immune Defic Syndrome 22, 31–38.

    Article  CAS  Google Scholar 

  109. Piscitelli, S.C., Amatea, M.A., Vogel, S., Bechtel, C, Metcalf, J.A., and Kovacs, J.A. (1996) Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrob. Agents Chemother. 40, 161–165.

    PubMed  CAS  Google Scholar 

  110. Fortis, C, Soldini, L., Ghezzi, S., Colombo, S., Tambussi, G., Vicenzi, E., et al. (2002) Tumor necrosis factor-α, interleukin-2 (IL-2), and soluble IL-2 receptor levels in human immunodeficiency virus-1 infected individuals receiving intermittent cycles of IL-2. AIDS Res. Hum. Retrovir. 18, 491–499.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Guido Poli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudio Fortis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adriano Lazzarin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Tambussi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Surgery and Molecular Sciences, VA Medical Center, University of Tennessee, Memphis, TN, USA

    Malak Kotb PhD

  2. Division of Infectious Diseases, Department of Internal Medicine, Centre Hospital Universitaire Vaudois, Lausanne, Switzerland

    Thierry Calandra MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Poli, G., Fortis, C., Lazzarin, A., Tambussi, G. (2003). Interleukin-2 for the Treatment of HIV Infection. In: Kotb, M., Calandra, T. (eds) Cytokines and Chemokines in Infectious Diseases Handbook. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-309-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-309-5_24

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-247-6

  • Online ISBN: 978-1-59259-309-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation